



**EXPRESS MAIL NO.: EV335859946US**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of:	George ZABRECKY	Confirmation No.:	5525
Serial No.:	10/726,824	Art Unit:	1614
Filed:	December 3, 2003	Examiner:	To be assigned
For:	COMPOSITIONS AND METHODS USEFUL FOR TREATING AND PREVENTING CHRONIC LIVER DISEASE, CHRONIC HCV INFECTION AND NON- ALCOHOLIC STEATOHEPATITIS	Attorney Docket No.:	11352-004-999

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. § 1.56 AND § 1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the U.S. Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the subject application which are or may be material to the patentability of any claim of the application, Attorneys for Applicant respectfully direct the Examiner's attention to references C01-C79 which are listed on the attached revised PTO/SB/08 Form entitled "List of References Cited by Applicant." A copy of references C01-C79 are submitted herewith.

Applicant respectfully requests that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, it is believed that no fee is due in connection herewith. However, should the Patent and Trademark Office determine otherwise, please charge the required fee to Jones Day Deposit Account No. 503013.

Respectfully submitted,

Date: May 14, 2004

  
Adriane M. Antler 32,605  
(Reg. No.)  
**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, New York 10017  
(212) 326-3939

Enclosures



EXPRESS MAIL NO.: EV335859946US

LIST OF REFERENCES CITED BY APPLICANT  
(Use several sheets if necessary)

ATTY DOCKET NO.

11352-004-999

APPLICATION NO.

10/726,824

APPLICANT

George ZABRECKY

FILING DATE

December 3, 2003

GROUP

1614

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Abe Y. <i>et al.</i> Effectiveness of interferon, glycyrrhizin combination therapy in patients with chronic hepatitis C. <i>Nippon Rinsho</i> . 1994; 52(7):1817-22 (in Japanese with English abstract)
C02	Arase Y. <i>et al.</i> The long term efficacy of glycyrrhizin in chronic hepatitis C patients. <i>Cancer</i> 1997; 79(8):1494-500
C03	Barbaro G. <i>et al.</i> Hepatic glutathione deficiency in chronic hepatitis C: quantitative evaluation in patients who are HIV positive and HIV negative and correlations with plasmatic and lymphocytic concentrations and with the activity of the liver disease. <i>Am J Gastroenterol</i> . 1996; 91(12):2569-73
C04	Berkson B.M. A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories. <i>Med Klin</i> . 1999; 94 Suppl 3:84-9
C05	Boigk G. <i>et al.</i> Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. <i>Hepatology</i> 1997; 26(3):643-649
C06	Boya P. <i>et al.</i> Antioxidant status and glutathione metabolism in peripheral blood mononuclear cells from patients with chronic hepatitis C. <i>J Hepatol</i> . 1999; 31(5):808-14
C07	Bustamante J. <i>et al.</i> , Alpha-lipoic acid in liver metabolism and disease. <i>Free Radic Biol Med</i> . 1998; 24(6):1023-39
C08	Buzzelli G. <i>et al.</i> A pilot study on the liver protective effect of silybin phosphatidylcholine complex (1dB1016) in chronic active hepatitis. <i>Int J Clin Pharmacol Ther Toxicol</i> . 1993; 31:456-460
C09	Chrobot A.M. <i>et al.</i> Antioxidant defense in children with chronic viral hepatitis B and C. <i>Med Sci Monit</i> 2000; 6(4): 713-8
C10	Cook G.C. <i>et al.</i> Results of a controlled clinical trial of glutathione in cases of hepatic cirrhosis. <i>Gut</i> 1965; 6(5):472-6
C11	Dehmlow C. <i>et al.</i> Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. <i>Hepatology</i> 1996; 23:749-754
C12	Eberhardt G. <i>et al.</i> Controlled study of the therapeutic effect of B vitamins and an anabolic steroid in chronic hepatitis. <i>Dtsch Med Wochenschr</i> . 1975; 100(41):2074-82 (in German with English abstract)
C13	Feher I. <i>et al.</i> Liver-protective action of silymarin therapy in chronic alcoholic liver diseases. <i>Orv Hetil</i> . 1989; 130:2723-2727 (in Hungarian with English abstract)
C14	Ferenci P. <i>et al.</i> , Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. <i>J Hepatol</i> . 1989; 9:105-113
C15	Fujisawa Y. <i>et al.</i> Glycyrrhizin inhibits the lytic pathway of complement - possible mechanism of its anti-inflammatory effect on liver cells in viral hepatitis. <i>Microbiol Immunol</i> . 2000; 44(9):799-804
C16	Gagliardi B. <i>et al.</i> , Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centers. <i>Med Klin</i> . 1978; 73:1060-1065
C17	Gut J. <i>et al.</i> Mechanisms of halothane toxicity: novel insights. <i>Pharmacol Ther</i> . 1993; 58(2): 133-55
C18	Hargreaves R.J. <i>et al.</i> Studies on the effects of L-ascorbic acid on acetaminophen-induced hepatotoxicity. II. An <i>in vivo</i> assessment in mice of the protection afforded by various dosage forms of ascorbate. <i>Toxicol Appl Pharmacol</i> . 1982; 64(3):380-92

C19	Hill D.B. <i>et al.</i> Antioxidants attenuate nuclear factor-kappa B activation and tumor necrosis factor-alpha production in alcoholic hepatitis patient monocytes and rat Kupffer cells, in vitro. <i>Clin Biochem.</i> 1999; 32(7):563-70
C20	Houglum K. <i>et al.</i> A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. <i>Gastroenterology</i> 1997; 113(4): 1069-73
C21	Hruby K. <i>et al.</i> Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. <i>Hum Toxicol.</i> 1983; 2:183-195
C22	Iimuro Y. <i>et al.</i> The glutathione precursor L-2-oxothiazolidine-4-carboxylic acid protects against liver injury due to chronic enteral ethanol exposure in the rat. <i>Hepatology</i> 2000; 31(2): 391-8
C23	Iino S. <i>et al.</i> Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis. <i>Hepatol Res.</i> 2001; 19(1): 31-40
C24	Kang S.Y. <i>et al.</i> Hepatoprotective activity of scopoletin, a constituent of Solarium lyratum. <i>Arch Pharm Res.</i> 1998; 21(6): 718-22
C25	Khodykin A.V. The efficacy of a diet enriched by lipotropic factors, and vitamin C and vitamin B-complex in patients with chronic hepatitis. <i>Vopr Pitan.</i> 1958; 17(2):19-29 (in Russian with English summary)
C26	Komar VI. Application of vitamin B12 in combined treatment of viral hepatitis. <i>Vopr Pitan.</i> 1982; (1):26-9 (in Russian with English summary)
C27	Li X.J., Scavenging effects on active oxygen radicals by schizandrins with different structures and configurations. <i>Free Radic Biol Med.</i> 1990; 9(2):99-104
C28	Liu G.T. Pharmacological actions and clinical use of fructus schizandrae. <i>Chin Med J. (Engl)</i> 1989;102(10):740-9
C29	Liu K.T., Pharmacological properties of Dibenzo[a,c]cyclooctene derivatives isolated from Fructus Schisandra Chinensis III. Inhibitory effects on carbon tetrachloride-induced lipid peroxidation, metabolism and covalent binding of carbon tetrachloride to lipids. <i>Chem Biol Interact.</i> 1982; 41(1):39-47
C30	Liu S.L. <i>et al.</i> Vitamin E therapy of acute CCl4-induced hepatic injury in mice is associated with inhibition of nuclear factor kappa B binding. <i>Hepatology</i> 1995; 22(5):1474-81
C31	Loguercio C. <i>et al.</i> Alpha-glutathione transferases in HCV-related chronic hepatitis: a new predictive index of response to interferon therapy? <i>J Hepatol.</i> 1998; 28(3):390-5
C32	Look M.P. <i>et al.</i> Interferon/antioxidant combination therapy for chronic hepatitis C - a controlled pilot trial. <i>Antiviral Res.</i> 1999; 43(2):113-22
C33	Lu H. <i>et al.</i> , Effect of dibenzo[a,c]cyclooctene lignans isolated from Fructus schizandrae on lipid peroxidation and anti-oxidative enzyme activity. <i>Chem Biol Interact.</i> 1991; 78(1):77-84
C34	Luper S. A review of plants used in the treatment of liver disease: Part 1. <i>Altern Med Rev.</i> 1998; 3:410-421
C35	Magliulo E. <i>et al.</i> Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres. <i>Med Klin.</i> 1978 Jul 14; 73(28-29): 1060-5 (in German with English summary)
C36	Mahmood S. <i>et al.</i> Effect of vitamin E on serum aminotransferase and thioredoxin levels in patients with viral hepatitis C. <i>Free Radic Res.</i> 2003; 37(7):781-5
C37	Marshall A.W. <i>et al.</i> Treatment of alcohol-related liver disease with thioctic acid: a six month randomized double-blind trial. <i>Gut</i> 1982; 23(12):1088-93
C38	Matsuo K. <i>et al.</i> Lamivudine and glycyrrhizin for treatment of chemotherapy-induced hepatitis B virus (HBV) hepatitis in a chronic HBV carrier with non-Hodgkin lymphoma. <i>Leuk Lymphoma</i> 2001; 41(1-2): 191-5
C39	McPartland J.M. Viral hepatitis treated with Phyllanthus amarus and milk thistle (Silybum marianum). <i>Complementary Medicine International</i> 1996; March/April: 40-42
C40	Meydani S.N. <i>et al.</i> Vitamin E supplementation and in vivo immune response in healthy elderly subjects. A randomized controlled trial. <i>JAMA</i> 1997; 277(17): 1380-6
C41	Mitra A. <i>et al.</i> Effect of ascorbic acid esters on hepatic glutathione levels in mice treated with a hepatotoxic dose of acetaminophen. <i>J Biochem Toxicol.</i> 1991; 6(2):93-100
C42	Moller E. <i>et al.</i> A contribution to the treatment of chronic liver diseases <i>Med Klin.</i> 1976; 71(43):1831-5
C43	Morazzoni P. <i>et al.</i> , Comparative pharmacokinetics of silipide and silymarin in rats. <i>Eur J Drug Metab Pharmacokinet.</i> 1993; 18:289-297
C44	Moscarella S. <i>et al.</i> , Therapeutic and antilipoperoxidant effects of silybin-phosphatidylcholine complex in chronic liver disease: preliminary results. <i>Curr Ther Res.</i> 1993; 53:98-102
C45	Nagita A. <i>et al.</i> Assessment of hepatic vitamin E status in adult patients with liver disease. <i>Hepatology</i> 1997; 26(2):392-7
C46	Nakashima T. <i>et al.</i> Thioredoxin levels in the sera of untreated viral hepatitis patients and those treated with glycyrrhizin or ursodeoxycholic acid. <i>Antioxid Redox Signal.</i> 2000 Winter; 2(4):687-94
C47	Numazaki K. <i>et al.</i> Effect of glycyrrhizin in children with liver dysfunction associated with cytomegalovirus infection. <i>Tohoku J Exp Med.</i> 1994; 172(2):147-53
C48	Okamoto T. The protective effect of glycyrrhizin on anti-Fas antibody-induced hepatitis in mice. <i>Eur J Pharmacol.</i> 2000; 387(2): 229-32.
C49	Okamoto T. <i>et al.</i> Glycyrrhizin protects mice from concanavalin A-induced hepatitis without affecting cytokine expression. <i>Int J Mol Med.</i> 1999; 4(2):149-52
C50	Patrick L. Hepatitis C: epidemiology and review of complementary/alternative medicine treatments. <i>Altern Med Rev.</i> 1999; 4(4):220-38
C51	Pauling L. Vitamin C prophylaxis for posttransfusion hepatitis. <i>Am J Clin Nutr.</i> 1981; 34(9):1978-80
C52	Rambousek V. <i>et al.</i> Severe Amanita phalloides poisoning in a 7-year-old girl. <i>Cesk Pediatr.</i> 1993; 48:332-333 (in Czech with English summary)
C53	Ravindranath V. <i>et al.</i> Effect of modulators of glutathione synthesis on the hepatotoxicity of 2-methylfuran. <i>Biochem Pharmacol</i> 1991; 41(9): 1311-8
C54	Rocchi E. <i>et al.</i> Antioxidant liposoluble vitamins and carotenoids in chronic hepatitis. 2001; 12(2):116-121

**EXPRESS MAIL NO.: EV335859946US**


C55	Sabeel A.I. <i>et al.</i> Intensive hemodialysis and hemoperfusion treatment of Amanita mushroom poisoning. <i>Mycopathologia</i> 1995; 131:107-114
C56	Salmi H.A. <i>et al.</i> Effect of silymarin on chemical, functional, and morphological alterations of the liver; A double blind controlled study. <i>Scand J Gastroenterol.</i> 1982; 17:517-521
C57	Schalm S.W. <i>et al.</i> New treatment strategies in non-responder patients with chronic hepatitis C. <i>J Hepatol.</i> 1999; 31 Suppl 1:184-8
C58	Shibata S. A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. <i>Yakugaku Zasshi</i> 2000; 120(10): 849-62
C59	Sinclair S. Chinese herbs: a clinical review of Astragalus, Ligusticum, and Schizandrae. <i>Altern Med Rev.</i> 1998; 3(5): 338-44
C60	Speck R.F. <i>et al.</i> Prednisolone stimulates hepatic glutathione synthesis in mice. Protection by prednisolone against acetaminophen hepatotoxicity in vivo. <i>J Hepatol.</i> 1993; 18(1): 62-7
C61	Sun F. <i>et al.</i> Evaluation of oxidative stress based on lipid hydroperoxide, vitamin C and vitamin E during apoptosis and necrosis caused by thioacetamide in rat liver. <i>Biochim Biophys Acta.</i> 2000;1500(2):181-5
C62	Sun F. <i>et al.</i> Evaluation of oxidative stress during apoptosis and necrosis caused by carbon tetrachloride in rat liver. <i>Biochim Biophys Acta.</i> 2001;1535(2):186-91
C63	Swietek K. <i>et al.</i> Reduced glutathione concentration in erythrocytes of patients with acute and chronic viral hepatitis. <i>J Viral Hepatol.</i> 1997; 4:139-41
C64	Takyar S.S. <i>et al.</i> Vitamin B12 stalls the 80 S ribosomal complex on the hepatitis C internal ribosome entry site. <i>J Mol Biol.</i> 2002; 319(1):1-8
C65	Tandon A. <i>et al.</i> Treatment of subacute hepatitis with Lamivudine and intravenous Glycyrrhizin: a pilot study. <i>Hepatol Res.</i> 2001; 20(1): 1-8
C66	Tanyalcin T. <i>et al.</i> The effects of chronic hepatitis C and B virus infections on liver reduced and oxidized glutathione concentrations. <i>Hepatol Res.</i> 2000; 18(2):104-109
C67	Tsubota A. <i>et al.</i> Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients. <i>Eur J Gastroenterol Hepatol.</i> 1999; 11(10):1077-83
C68	Valenzuela A. <i>et al.</i> Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. <i>Biol Res.</i> 1994; 27(2):105-12
C69	Vailati A. <i>et al.</i> Randomized open study of the dose-effect relationship of a short course of IdB 1016 in patients with viral or alcoholic hepatitis. <i>Fitoterapia</i> 1993; 64:219-228
C70	van Rossum T.G. <i>et al.</i> Pharmacokinetics of intravenous glycyrrhizin after single and multiple doses in patients with chronic hepatitis C infection. <i>Clin Ther.</i> 1999; 21(12):2080-90
C71	van Rossum T.G. <i>et al.</i> Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. <i>J Gastroenterol Hepatol.</i> 1999; 14(11):1093-1099
C72	van Rossum T.G. <i>et al.</i> Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. <i>Aliment Pharmacol Ther.</i> 1998; 12(3):199-205
C73	Vendermiale G. <i>et al.</i> Oxidative stress in symptom-free HCV carriers: relation with ALT flare-up. <i>Eur J Clin Invest.</i> 2001; 31(1):54-63
C74	Vogel G. <i>et al.</i> Protection by silibinin against Amanita phalloides intoxication in beagles. <i>Toxicol Appl Pharmacol.</i> 1984; 73:355-362
C75	von Herbay A. <i>et al.</i> Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomized, double-blind, placebo-controlled study. <i>Free Radic Res.</i> 1997; 27(6):599-605
C76	von Herbay A. <i>et al.</i> Diminished plasma levels of vitamin E in patients with severe viral hepatitis. <i>Free Radic Res.</i> 1996; 25(6):461-6
C77	Yamashiki M. <i>et al.</i> Effects of the Japanese herbal medicine "Sho-saiko-to" (TJ-9) on <i>in vitro</i> interleukin-10 production by peripheral blood mononuclear cells of patients with chronic hepatitis C. <i>Hepatology</i> 1997; 25(6):1390-7
C78	Yoshikawa M. <i>et al.</i> Mechanisms of Hepatocellular Injury: Effects of Glycyrrhizin on Immune-Mediated Cytotoxicity. <i>J Gastroenterol Hepatol.</i> 1997; 12(3):243-248
C79	Younes M. <i>et al.</i> Protection by exogenous glutathione against hypoxic and cyanide-induced damage to isolated perfused rat livers. <i>Toxicol Lett.</i> 1990; 50(2-3):229-36

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)



ATTY DOCKET NO.

11352-004-999

APPLICATION NO.

10/726,824

APPLICANT

George ZABRECKY

FILING DATE

December 3, 2003

GROUP

1614

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Abe Y. <i>et al.</i> Effectiveness of interferon, glycyrrhizin combination therapy in patients with chronic hepatitis C. <i>Nippon Rinsho</i> . 1994; 52(7):1817-22 (in Japanese with English abstract)
C02	Arase Y. <i>et al.</i> The long term efficacy of glycyrrhizin in chronic hepatitis C patients. <i>Cancer</i> 1997; 79(8):1494-500
C03	Barbaro G. <i>et al.</i> Hepatic glutathione deficiency in chronic hepatitis C: quantitative evaluation in patients who are HIV positive and HIV negative and correlations with plasmatic and lymphocytic concentrations and with the activity of the liver disease. <i>Am J Gastroenterol</i> . 1996; 91(12):2569-73
C04	Berkson B.M. A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories. <i>Med Klin</i> . 1999; 94 Suppl 3:84-9
C05	Boigk G. <i>et al.</i> Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. <i>Hepatology</i> 1997; 26(3):643-649
C06	Boya P. <i>et al.</i> Antioxidant status and glutathione metabolism in peripheral blood mononuclear cells from patients with chronic hepatitis C. <i>J Hepatol</i> . 1999; 31(5):808-14
C07	Bustamante J. <i>et al.</i> , Alpha-lipoic acid in liver metabolism and disease. <i>Free Radic Biol Med</i> . 1998; 24(6):1023-39
C08	Buzzelli G. <i>et al.</i> A pilot study on the liver protective effect of silybin phosphatidylcholine complex (1dB1016) in chronic active hepatitis. <i>Int J Clin Pharmacol Ther Toxicol</i> . 1993; 31:456-460
C09	Chrobot A.M. <i>et al.</i> Antioxidant defense in children with chronic viral hepatitis B and C. <i>Med Sci Monit</i> 2000; 6(4): 713-8
C10	Cook G.C. <i>et al.</i> Results of a controlled clinical trial of glutathione in cases of hepatic cirrhosis. <i>Gut</i> 1965; 6(5):472-6
C11	Dehmlow C. <i>et al.</i> Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. <i>Hepatology</i> 1996; 23:749-754
C12	Eberhardt G. <i>et al.</i> Controlled study of the therapeutic effect of B vitamins and an anabolic steroid in chronic hepatitis. <i>Dtsch Med Wochenschr</i> . 1975; 100(41):2074-82 (in German with English abstract)
C13	Fehér I. <i>et al.</i> Liver-protective action of silymarin therapy in chronic alcoholic liver diseases. <i>Orv Hetil</i> . 1989; 130:2723-2727 (in Hungarian with English abstract)
C14	Ferenc P. <i>et al.</i> , Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. <i>J Hepatol</i> . 1989; 9:105-113
C15	Fujisawa Y. <i>et al.</i> Glycyrrhizin inhibits the lytic pathway of complement - possible mechanism of its anti-inflammatory effect on liver cells in viral hepatitis. <i>Microbiol Immunol</i> . 2000; 44(9):799-804
C16	Gagliardi B. <i>et al.</i> , Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centers. <i>Med Klin</i> . 1978; 73:1060-1065
C17	Gut J. <i>et al.</i> Mechanisms of halothane toxicity: novel insights. <i>Pharmacol Ther</i> . 1993; 58(2): 133-55
C18	Hargreaves R.J. <i>et al.</i> Studies on the effects of L-ascorbic acid on acetaminophen-induced hepatotoxicity. II. An <i>in vivo</i> assessment in mice of the protection afforded by various dosage forms of ascorbate. <i>Toxicol Appl Pharmacol</i> . 1982; 64(3):380-92
C19	Hill D.B. <i>et al.</i> Antioxidants attenuate nuclear factor-kappa B activation and tumor necrosis factor-alpha production in

		alcoholic hepatitis patient monocytes and rat Kupffer cells, in vitro. <i>Clin Biochem.</i> 1999; 32(7):563-70
	C20	Houglum K. <i>et al.</i> A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. <i>Gastroenterology</i> 1997; 113(4): 1069-73
	C21	Hruby K. <i>et al.</i> Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. <i>Hum Toxicol.</i> 1983; 2:183-195
	C22	Iimuro Y. <i>et al.</i> The glutathione precursor L-2-oxothiazolidine-4-carboxylic acid protects against liver injury due to chronic enteral ethanol exposure in the rat. <i>Hepatology</i> 2000; 31(2): 391-8
	C23	Iino S. <i>et al.</i> Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis. <i>Hepatol Res.</i> 2001; 19(1): 31-40
	C24	Kang S.Y. <i>et al.</i> Hepatoprotective activity of scopoletin, a constituent of Solarium lyratum. <i>Arch Pharm Res.</i> 1998; 21(6): 718-22
	C25	Khodykin A.V. The efficacy of a diet enriched by lipotropic factors, and vitamin C and vitamin B-complex in patients with chronic hepatitis. <i>Vopr Pitan.</i> 1958; 17(2):19-29 (in Russian with English summary)
	C26	Komar VI. Application of vitamin B12 in combined treatment of viral hepatitis. <i>Vopr Pitan.</i> 1982; (1):26-9 (in Russian with English summary)
	C27	Li X.J., Scavenging effects on active oxygen radicals by schizandrins with different structures and configurations. <i>Free Radic Biol Med.</i> 1990; 9(2):99-104
	C28	Liu G.T. Pharmacological actions and clinical use of fructus schizandrae. <i>Chin Med J. (Engl)</i> 1989;102(10):740-9
	C29	Liu K.T., Pharmacological properties of Dibenzo[a,c]cyclooctene derivatives isolated from Fructus Schisandra Chinensis III. Inhibitory effects on carbon tetrachloride-induced lipid peroxidation, metabolism and covalent binding of carbon tetrachloride to lipids. <i>Chem Biol Interact.</i> 1982; 41(1):39-47
	C30	Liu S.L. <i>et al.</i> Vitamin E therapy of acute CCl4-induced hepatic injury in mice is associated with inhibition of nuclear factor kappa B binding. <i>Hepatology</i> 1995; 22(5):1474-81
	C31	Loguercio C. <i>et al.</i> Alpha-glutathione transferases in HCV-related chronic hepatitis: a new predictive index of response to interferon therapy? <i>J Hepatol.</i> 1998; 28(3):390-5
	C32	Look M.P. <i>et al.</i> Interferon/antioxidant combination therapy for chronic hepatitis C - a controlled pilot trial. <i>Antiviral Res.</i> 1999; 43(2):113-22
	C33	Lu H. <i>et al.</i> , Effect of dibenzo[a,c]cyclooctene lignans isolated from Fructus schizandrae on lipid peroxidation and anti-oxidative enzyme activity. <i>Chem Biol Interact.</i> 1991; 78(1):77-84
	C34	Luper S. A review of plants used in the treatment of liver disease: Part 1. <i>Altern Med Rev.</i> 1998; 3:410-421
	C35	Magliulo E. <i>et al.</i> Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres. <i>Med Klin.</i> 1978 Jul 14; 73(28-29): 1060-5 (in German with English summary)
	C36	Mahmood S. <i>et al.</i> Effect of vitamin E on serum aminotransferase and thioredoxin levels in patients with viral hepatitis C. <i>Free Radic Res.</i> 2003; 37(7):781-5
	C37	Marshall A.W. <i>et al.</i> Treatment of alcohol-related liver disease with thioctic acid: a six month randomized double-blind trial. <i>Gut</i> 1982; 23(12):1088-93
	C38	Matsuo K. <i>et al.</i> Lamivudine and glycyrrhizin for treatment of chemotherapy-induced hepatitis B virus (HBV) hepatitis in a chronic HBV carrier with non-Hodgkin lymphoma. <i>Leuk Lymphoma</i> 2001; 41(1-2): 191-5
	C39	McPartland J.M. Viral hepatitis treated with Phyllanthus amarus and milk thistle (Silybum marianum). <i>Complementary Medicine International</i> 1996; March/April: 40-42
	C40	Meydani S.N. <i>et al.</i> Vitamin E supplementation and in vivo immune response in healthy elderly subjects. A randomized controlled trial. <i>JAMA</i> 1997; 277(17): 1380-6
	C41	Mitra A. <i>et al.</i> Effect of ascorbic acid esters on hepatic glutathione levels in mice treated with a hepatotoxic dose of acetaminophen. <i>J Biochem Toxicol.</i> 1991; 6(2):93-100
	C42	Moller E. <i>et al.</i> A contribution to the treatment of chronic liver diseases <i>Med Klin.</i> 1976; 71(43):1831-5
	C43	Morazzoni P. <i>et al.</i> , Comparative pharmacokinetics of silipide and silymarin in rats. <i>Eur J Drug Metab Pharmacokinet.</i> 1993; 18:289-297
	C44	Moscarella S. <i>et al.</i> , Therapeutic and antilipoperoxidant effects of silybin-phosphatidylcholine complex in chronic liver disease: preliminary results. <i>Curr Ther Res.</i> 1993; 53:98-102
	C45	Nagita A. <i>et al.</i> Assessment of hepatic vitamin E status in adult patients with liver disease. <i>Hepatology</i> 1997; 26(2):392-7
	C46	Nakashima T. <i>et al.</i> Thioredoxin levels in the sera of untreated viral hepatitis patients and those treated with glycyrrhizin or ursodeoxycholic acid. <i>Antioxid Redox Signal.</i> 2000 Winter; 2(4):687-94
	C47	Numazaki K. <i>et al.</i> Effect of glycyrrhizin in children with liver dysfunction associated with cytomegalovirus infection. <i>Tohoku J Exp Med.</i> 1994; 172(2):147-53
	C48	Okamoto T. The protective effect of glycyrrhizin on anti-Fas antibody-induced hepatitis in mice. <i>Eur J Pharmacol.</i> 2000; 387(2): 229-32.
	C49	Okamoto T. <i>et al.</i> Glycyrrhizin protects mice from concanavalin A-induced hepatitis without affecting cytokine expression. <i>Int J Mol Med.</i> 1999; 4(2):149-52
	C50	Patrick L. Hepatitis C: epidemiology and review of complementary/alternative medicine treatments. <i>Altern Med Rev.</i> 1999; 4(4):220-38
	C51	Pauling L. Vitamin C prophylaxis for posttransfusion hepatitis. <i>Am J Clin Nutr.</i> 1981; 34(9):1978-80
	C52	Rambousek V. <i>et al.</i> Severe Amanita phalloides poisoning in a 7-year-old girl. <i>Cesk Pediatr.</i> 1993; 48:332-333 (in Czech with English summary)
	C53	Ravindranath V. <i>et al.</i> Effect of modulators of glutathione synthesis on the hepatotoxicity of 2-methylfuran. <i>Biochem Pharmacol</i> 1991; 41(9): 1311-8
	C54	Rocchi E. <i>et al.</i> Antioxidant liposoluble vitamins and carotenoids in chronic hepatitis. 2001; 12(2):116-121

C55	Sabeel A.I. <i>et al.</i> Intensive hemodialysis and hemoperfusion treatment of Amanita mushroom poisoning. <i>Mycopathologia</i> 1995; 131:107-114
C56	Salmi H.A. <i>et al.</i> Effect of silymarin on chemical, functional, and morphological alterations of the liver; A double blind controlled study. <i>Scand J Gastroenterol.</i> 1982; 17:517-521
C57	Schalm S.W. <i>et al.</i> New treatment strategies in non-responder patients with chronic hepatitis C. <i>J Hepatol.</i> 1999; 31 Suppl 1:184-8
C58	Shibata S. A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. <i>Yakugaku Zasshi</i> 2000; 120(10): 849-62
C59	Sinclair S. Chinese herbs: a clinical review of Astragalus, Ligusticum, and Schizandrae. <i>Altern Med Rev.</i> 1998; 3(5): 338-44
C60	Speck R.F. <i>et al.</i> Prednisolone stimulates hepatic glutathione synthesis in mice. Protection by prednisolone against acetaminophen hepatotoxicity in vivo. <i>J Hepatol.</i> 1993; 18(1): 62-7
C61	Sun F. <i>et al.</i> Evaluation of oxidative stress based on lipid hydroperoxide, vitamin C and vitamin E during apoptosis and necrosis caused by thioacetamide in rat liver. <i>Biochim Biophys Acta.</i> 2000;1500(2):181-5
C62	Sun F. <i>et al.</i> Evaluation of oxidative stress during apoptosis and necrosis caused by carbon tetrachloride in rat liver. <i>Biochim Biophys Acta.</i> 2001;1535(2):186-91
C63	Swietek K. <i>et al.</i> Reduced glutathione concentration in erythrocytes of patients with acute and chronic viral hepatitis. <i>J Viral Hepatol.</i> 1997; 4:139-41
C64	Takyar S.S. <i>et al.</i> Vitamin B12 stalls the 80 S ribosomal complex on the hepatitis C internal ribosome entry site. <i>J Mol Biol.</i> 2002; 319(1):1-8
C65	Tandon A. <i>et al.</i> Treatment of subacute hepatitis with Lamivudine and intravenous Glycyrrhizin: a pilot study. <i>Hepatol Res.</i> 2001; 20(1): 1-8
C66	Tanyalcin T. <i>et al.</i> The effects of chronic hepatitis C and B virus infections on liver reduced and oxidized glutathione concentrations. <i>Hepatol Res.</i> 2000; 18(2):104-109
C67	Tsubota A. <i>et al.</i> Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients. <i>Eur J Gastroenterol Hepatol.</i> 1999; 11(10):1077-83
C68	Valenzuela A. <i>et al.</i> Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. <i>Biol Res.</i> 1994; 27(2):105-12
C69	Vailati A. <i>et al.</i> Randomized open study of the dose-effect relationship of a short course of IdB 1016 in patients with viral or alcoholic hepatitis. <i>Fitoterapia</i> 1993; 64:219-228
C70	van Rossum T.G. <i>et al.</i> Pharmacokinetics of intravenous glycyrrhizin after single and multiple doses in patients with chronic hepatitis C infection. <i>Clin Ther.</i> 1999; 21(12):2080-90
C71	van Rossum T.G. <i>et al.</i> Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. <i>J Gastroenterol Hepatol.</i> 1999; 14(11):1093-1099
C72	van Rossum T.G. <i>et al.</i> Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. <i>Aliment Pharmacol Ther.</i> 1998; 12(3):199-205
C73	Vendermiale G. <i>et al.</i> Oxidative stress in symptom-free HCV carriers: relation with ALT flare-up. <i>Eur J Clin Invest.</i> 2001; 31(1):54-63
C74	Vogel G. <i>et al.</i> Protection by silibinin against Amanita phalloides intoxication in beagles. <i>Toxicol Appl Pharmacol.</i> 1984; 73:355-362
C75	von Herbay A. <i>et al.</i> Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomized, double-blind, placebo-controlled study. <i>Free Radic Res.</i> 1997; 27(6):599-605
C76	von Herbay A. <i>et al.</i> Diminished plasma levels of vitamin E in patients with severe viral hepatitis. <i>Free Radic Res.</i> 1996; 25(6):461-6
C77	Yamashiki M. <i>et al.</i> Effects of the Japanese herbal medicine "Sho-saiko-to" (TJ-9) on <i>in vitro</i> interleukin-10 production by peripheral blood mononuclear cells of patients with chronic hepatitis C. <i>Hepatology</i> 1997; 25(6):1390-7
C78	Yoshikawa M. <i>et al.</i> Mechanisms of Hepatocellular Injury: Effects of Glycyrrhizin on Immune-Mediated Cytotoxicity. <i>J Gastroenterol Hepatol.</i> 1997; 12(3):243-248
C79	Younes M. <i>et al.</i> Protection by exogenous glutathione against hypoxic and cyanide-induced damage to isolated perfused rat livers. <i>Toxicol Lett.</i> 1990; 50(2-3):229-36

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	